Choose your preferred way to stay informed of new case launches and settlement deadlines
Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively." Following this news, shares of Biomea fell over 59% in after hours trading on the same day.
In order to be eligible to join the BMEA class action lawsuit, you must have incurred a loss on shares of Biomea Fusion, Inc. purchased during the class period listed above.
TOP
